vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
STURM RUGER & CO INC is the larger business by last-quarter revenue ($151.1M vs $86.8M, roughly 1.7× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 3.6%). STURM RUGER & CO INC produced more free cash flow last quarter ($12.3M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 5.1%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
IOVA vs RGR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $151.1M |
| Net Profit | — | — |
| Gross Margin | 67.4% | 17.8% |
| Operating Margin | -84.7% | 2.3% |
| Net Margin | — | — |
| Revenue YoY | 17.7% | 3.6% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $151.1M | ||
| Q3 25 | $67.5M | $126.8M | ||
| Q2 25 | $60.0M | $132.5M | ||
| Q1 25 | $49.3M | $135.7M | ||
| Q4 24 | $73.7M | $145.8M | ||
| Q3 24 | $58.6M | $122.3M | ||
| Q2 24 | $31.1M | $130.8M | ||
| Q1 24 | $715.0K | $136.8M |
| Q4 25 | — | — | ||
| Q3 25 | $-91.3M | $1.6M | ||
| Q2 25 | $-111.7M | $-17.2M | ||
| Q1 25 | $-116.2M | $7.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-83.5M | $4.7M | ||
| Q2 24 | $-97.1M | $8.3M | ||
| Q1 24 | $-113.0M | $7.1M |
| Q4 25 | 67.4% | 17.8% | ||
| Q3 25 | 43.0% | 15.1% | ||
| Q2 25 | 5.5% | 3.9% | ||
| Q1 25 | -0.8% | 22.0% | ||
| Q4 24 | 68.7% | 22.8% | ||
| Q3 24 | 46.2% | 18.5% | ||
| Q2 24 | -0.8% | 22.3% | ||
| Q1 24 | — | 21.5% |
| Q4 25 | -84.7% | 2.3% | ||
| Q3 25 | -140.7% | -2.7% | ||
| Q2 25 | -189.8% | -15.6% | ||
| Q1 25 | -245.8% | 6.2% | ||
| Q4 24 | -117.5% | 7.8% | ||
| Q3 24 | -152.1% | 3.1% | ||
| Q2 24 | -327.6% | 6.9% | ||
| Q1 24 | -16464.6% | 5.5% |
| Q4 25 | — | — | ||
| Q3 25 | -135.3% | 1.2% | ||
| Q2 25 | -186.2% | -13.0% | ||
| Q1 25 | -235.5% | 5.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -142.7% | 3.9% | ||
| Q2 24 | -312.2% | 6.3% | ||
| Q1 24 | -15800.8% | 5.2% |
| Q4 25 | — | $0.22 | ||
| Q3 25 | — | $0.10 | ||
| Q2 25 | $-0.33 | $-1.05 | ||
| Q1 25 | $-0.36 | $0.46 | ||
| Q4 24 | $-0.24 | $0.62 | ||
| Q3 24 | $-0.28 | $0.28 | ||
| Q2 24 | $-0.34 | $0.47 | ||
| Q1 24 | $-0.42 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $92.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $283.8M |
| Total Assets | $913.2M | $342.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $92.5M | ||
| Q3 25 | $300.8M | $80.8M | ||
| Q2 25 | $301.2M | $101.4M | ||
| Q1 25 | $359.7M | $108.3M | ||
| Q4 24 | $323.8M | $105.5M | ||
| Q3 24 | $397.5M | $96.0M | ||
| Q2 24 | $412.5M | $105.6M | ||
| Q1 24 | $356.2M | $115.3M |
| Q4 25 | $698.6M | $283.8M | ||
| Q3 25 | $702.3M | $279.6M | ||
| Q2 25 | $698.5M | $289.3M | ||
| Q1 25 | $767.9M | $321.5M | ||
| Q4 24 | $710.4M | $319.6M | ||
| Q3 24 | $773.5M | $314.9M | ||
| Q2 24 | $768.5M | $321.5M | ||
| Q1 24 | $680.0M | $332.0M |
| Q4 25 | $913.2M | $342.0M | ||
| Q3 25 | $904.9M | $342.3M | ||
| Q2 25 | $907.4M | $349.5M | ||
| Q1 25 | $966.7M | $379.0M | ||
| Q4 24 | $910.4M | $384.0M | ||
| Q3 24 | $991.1M | $373.5M | ||
| Q2 24 | $964.3M | $376.7M | ||
| Q1 24 | $869.8M | $385.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $15.5M |
| Free Cash FlowOCF − Capex | $-61.9M | $12.3M |
| FCF MarginFCF / Revenue | -71.3% | 8.2% |
| Capex IntensityCapex / Revenue | 10.7% | 2.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $15.5M | ||
| Q3 25 | $-78.7M | $12.9M | ||
| Q2 25 | $-67.4M | $14.7M | ||
| Q1 25 | $-103.7M | $11.1M | ||
| Q4 24 | $-73.3M | $20.0M | ||
| Q3 24 | $-59.0M | $9.4M | ||
| Q2 24 | $-98.4M | $18.7M | ||
| Q1 24 | $-122.3M | $7.3M |
| Q4 25 | $-61.9M | $12.3M | ||
| Q3 25 | $-89.5M | $7.0M | ||
| Q2 25 | $-74.9M | $9.1M | ||
| Q1 25 | $-109.9M | $10.0M | ||
| Q4 24 | $-77.5M | $16.4M | ||
| Q3 24 | $-61.3M | $2.6M | ||
| Q2 24 | $-98.9M | $10.1M | ||
| Q1 24 | $-126.5M | $5.6M |
| Q4 25 | -71.3% | 8.2% | ||
| Q3 25 | -132.7% | 5.5% | ||
| Q2 25 | -124.9% | 6.9% | ||
| Q1 25 | -222.8% | 7.4% | ||
| Q4 24 | -105.1% | 11.2% | ||
| Q3 24 | -104.6% | 2.1% | ||
| Q2 24 | -317.9% | 7.7% | ||
| Q1 24 | -17685.3% | 4.1% |
| Q4 25 | 10.7% | 2.1% | ||
| Q3 25 | 16.1% | 4.6% | ||
| Q2 25 | 12.4% | 4.2% | ||
| Q1 25 | 12.6% | 0.8% | ||
| Q4 24 | 5.7% | 2.5% | ||
| Q3 24 | 3.9% | 5.5% | ||
| Q2 24 | 1.4% | 6.6% | ||
| Q1 24 | 583.4% | 1.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
